Comparison · NCT00326183-be2c2a60
Arm 1: VAQTA™ vs Arm 2: VAQTA™ +ProQuad™: Participants With 1 or More Systemic Adverse Experiences
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm 1: VAQTA™ vs Arm 2: VAQTA™ +ProQuad™: Participants With 1 or More Systemic Adverse Experiences. Trial comparisons, record NCT00326183-be2c2a60. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00326183-be2c2a60
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.553 | 0.527 | 0.578 | wilson | |
| Risk in group 2 | 0.59 | 0.536 | 0.641 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0372 | -0.0948 | 0.0222 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.937 | 0.847 | 1.04 | log | |
| Odds ratio, group 1 over group 2 | 0.859 | 0.675 | 1.09 | log | |
| Number needed to treat, for one fewer participant with the outcome on Arm 1: VAQTA™ than on Arm 2: VAQTA™ +ProQuad™ | 26.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm 1: VAQTA™ | Hepatitis A vaccine, inactivated | 782 | 1,415 | OG000 |
| Group 2 | Arm 2: VAQTA™ +ProQuad™ | Hepatitis A vaccine, inactivated + measles, mumps, rubella, and varicella vaccine live | 197 | 334 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Participants With 1 or More Systemic Adverse Experiences
- Description
- Time frame
- Days 1 to 14 After Any Vaccination
- Population
- Includes all subjects who provided safety follow-up data after any dose of vaccine out of the total number of subjects enrolled.
Source ClinicalTrials.gov
Trial
- Title
- Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)
- NCT number
- NCT00326183
- Phases
- PHASE4
- Conditions
- Hepatitis A, Measles, Mumps, Rubella, Chickenpox
- Interventions
- VAQTA®, ProQuad
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2008-11-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00326183?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00326183-be2c2a60